Most Recent Articles by Deborah Weinstein
An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo
First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.
Established products fueled at 12% jump in first-quarter sales.
The FDA asked private biotech Genervon to release all available clinical trial data for its experimental ALS treatment.
Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.
More Articles by Deborah Weinstein
The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.